Foxp3+ cells are running the show in patients with surgically resected nonsmall cell lung cancer

Nathalie Chaput1,2,4 and Aurelien Marabelle1,3,5

Affiliations: 1Gustave Roussy Cancer Campus, Villejuif, France. 2Laboratory of Immune monitoring in Oncology UMS 3655 CNRS/US 23 INSERM Gustave Roussy Cancer Campus, Villejuif, France. 3Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France. 4Cell Therapy Unit, Gustave Roussy Cancer Campus, Villejuif, France. 5Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France.

Correspondence: Nathalie Chaput, Laboratoire d’Immunomonitoring en Oncologie, UMS 3655 CNRS / US 23 INSERM, Laboratoire de Thérapie Cellulaire, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805 Villejuif, France. E-mail: nathalie.chaput@gustaveroussy.fr

@ERSpublications
Foxp3 microlocalisation dictates prognosis in NSCLC; CD8+ T-cells may influence prognosis in Treg-infiltrated tumours http://ow.ly/T9PwJ

Tumor lymphocyte infiltrates (TILs) have a significant impact on multiple cancers prognosis, but the diversity of TILs and the methodological challenges to analyse TIL infiltrates in a reliable manner render difficult the interpretation of data explaining that to date TIL infiltration is not used in daily clinical practice.

O’CALLAGHAN et al. [1] analysed the micro-localisation of T-cells (CD3 and CD8 positive cells) and regulatory T-cells (Treg; Foxp3-positive cells) in tumour specimens from 196 patients with stage IA–IIIA surgically resected nonsmall cell lung cancer (NSCLC). The authors selected patients who did not receive adjuvant treatment; this is of particular relevance since chemotherapy can modify immune functions [2] and could act as a confounder with respect to outcome. They determined the absolute number of immunohistochemistry-stained lymphocytes on whole-slide tumour specimens using a novel cell detection algorithm and reported as numbers of cells per mm² of tumour and stroma region. They calculated for each marker (CD3; CD8 and Foxp3) the ratio of corresponding tumour islet and stroma (TI/S) counts. Patients could then be classified as CD3+HIGH or CD3+LOW, CD8+HIGH and CD8+LOW and Foxp3+HIGH and Foxp3+LOW depending on whether TI/S ratio was above or below median value. Thus this study takes into account the regional distribution of lymphocyte subsets. Indeed, ratio allows for more specific information considering the infiltrate as a whole including the ability of lymphocytes to enter the tumour. The study of prognostic relevance of lymphocyte infiltration showed that the regional distribution of lymphocyte subsets may help identifying patients at risk of early relapse in a large population of surgically resected NSCLC. A positive association between CD8+HIGH and survival was observed with 59% of patients alive after 5 years versus 34% for those patients with a CD8+LOW pattern (p<0.001). Foxp3+HIGH was associated with a worse outcome with 20% of patients alive after 5 years versus 69% for those patients with a Foxp3+LOW pattern (p<0.001). Finally, no significant link with prognosis was observed with CD3 TI/S ratio. This is probably explained by the fact that CD3 allows identification of all T subsets, therefore a mixture of effector and Treg. Very interestingly, O’CALLAGHAN et al. [1] have also analysed the relationship between the absolute lymphocytes counts (cells per mm²) and prognosis. As would be expected, a high number of CD8+ cells and low number of Foxp3+ cells in the tumour islets were associated with a significant survival advantage while high number of Foxp3+ cells was associated with a worse outcome. Less expected was that high numbers of CD3+ and CD8+ cells in the stroma were associated with a poor outcome and high number of CD3+ cells in tumour islets had no significant
relationship with prognosis. Altogether these data demonstrate that taking into account the balance between peri- and intra-tumoural lymphocytes is critical for predicting survival in surgically resected NSCLC. CD8 and Foxp3 TI/S ratios were both independent predictors of survival and were stronger prognostic value than tumour stages according to the International System of Staging for Lung Cancer [3].

The prognostic value of CD8 and Foxp3 TI/S ratios was also explored. The four possible combinations (CD8^{HIGH}/Foxp3^{HIGH}, CD8^{HIGH}/Foxp3^{LOW}, CD8^{LOW}/Foxp3^{HIGH} and CD8^{LOW}/Foxp3^{LOW}) were examined with regard to prognosis. Surprisingly, tumour specimens with a low Foxp3 TI/S ratio have a favorable prognosis regardless of the CD8 TI/S ratio. Indeed the 5-year survival of CD8^{HIGH}/Foxp3^{LOW} and CD8^{LOW}/Foxp3^{LOW} was 73 and 77% respectively and median survival was not reached in these two groups. By contrast, tumour specimens with a high Foxp3 TI/S ratio have a worse prognosis but influenced by the CD8 TI/S ratio. Indeed, the median survival in the group of patients with the CD8^{HIGH}/Foxp3^{HIGH} was 31 months versus 17.2 months in the group of patients with CD8^{LOW}/Foxp3^{HIGH}. This indicates that Foxp3 micro-localisation dictates the prognosis and that CD8 T-cells may influence the prognosis only in tumours where the Treg TI/S ratio is high (figure 1). This work is in accordance with other studies showing the impact of tumour infiltrating Treg cells on patient with surgically resected NSCLC. Hanagiri and colleagues screened 131 patients who underwent complete surgical resection for stage I NSCLC [4]. The clinical significance of the relative expression of Foxp3 in the

![Schematic representation of the prognostic value by combining CD8 and Foxp3 tumour islet and stroma (TI/S) ratios.](image)

**FIGURE 1** Schematic representation of the prognostic value by combining CD8 and Foxp3 tumour islet and stroma (TI/S) ratios. **a)** Foxp3 TI/S ratio is high in both cases (left and right panels) but the CD8 TI/S ratio is high (left panel; CD8^{HIGH}/Foxp3^{HIGH}) or low (right panel; CD8^{LOW}/Foxp3^{HIGH}). Both patterns have a different 5-year survival. CD8 TI/S ratio highly influences patient outcomes with a 31-months median survival when CD8 TI/S ratio is high and only 17 months median survival when the CD8 TI/S ratio is low. **b)** Foxp3 TI/S ratio is low in both cases (left and right panels) but the CD8 TI/S ratio is high (left panel; CD8^{HIGH}/Foxp3^{LOW}) or low (right panel; CD8^{LOW}/Foxp3^{LOW}). Both patterns have a quiet similar 5-year survival. CD8 TI/S ratio does not significantly influence patient outcomes (77 and 73% 5-year survival respectively).
regional lymph nodes was explored. High expression of Foxp3 in the regional lymph nodes was associated with a poor prognostic factor in these patients. Previous study using flow cytometry demonstrated that the frequency of Foxp3+ cells in the regional lymph nodes was a significance prognostic factor in patients who underwent surgical resection for NSCLC [5]. Another recent work has shown that peripheral blood Foxp3+ cells could serve as a prognostic biomarker in NSCLC patients [6]. These works bring the first rationale for immune biomarkers in patients with surgically resected NSCLC that could help determining which individuals are at a higher risk of relapse after surgical resection, and who are indicated for treatment and follow-up examinations. Also Foxp3 pattern of expression may reflect the tumour immunogenicity and correlate with the mutational load of NSCLC tumours [7]. Such observation could point out that immunogenic tumours may have a poorer outcome probably due to an active participation of immunosuppressive mechanisms participating in the tumour outgrowth, survival, proliferation and dissemination. These studies support the hypothesis that Treg play a pivotal role in NSCLC, and that CD8+ T-cells are critical but their action is limited by the presence of Foxp3+ cells in these NSCLC patients. The characterisation of these differentially located tumour-infiltrative T-cells would be of great interest to know where the subsets of tumour-specific T-cells preferentially reside in the tumour bed. This is of peculiar interest in the current development of PD-1 and CTLA-4 immune checkpoint-targeted antibodies in NSCLC. Indeed, CTLA-4 is highly expressed at the membrane of tumour-specific Treg [8, 9], and PD-1 is a marker of exhausted tumour-specific CD8+ T-cells [10] and is also expressed by tumour-infiltrative Treg. Therefore, future studies of immune contexture in NSCLC should at least include an analysis of PD-1 expression on CD8+ and Foxp3+ T-cells. Such analysis could be performed on tumour biopsies prior a neo-adjuvant anti-PD-1/PD-L1 monotherapy. This would allow performing subsequent correlative studies between immune infiltrative patterns, response rates and level of immune reactivation (in the surgical piece). Indeed, it would make sense that anti-PD-1 monotherapy or the combination of anti-PD-1 and anti-CTLA-4 antibodies would provide different response rates within the four subsets of tumour types described by O’CALLAGHAN et al. [1] (figure 1).

Knowing the multiple ongoing and upcoming large immunotherapy trials in lung cancers, there are good chances that the groundwork for immune therapeutic stratification of NSCLC patients will emerge over the next couple of years.

References